利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

737 条记录 (耗时 0.039 秒)

    ZINC TRANSPORTER COMPOSITIONS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
    4.
    发明公开
    ZINC TRANSPORTER COMPOSITIONS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES 审中-公开
    锌转运组合物的心血管疾病治疗

    公开(公告)号：EP1545585A1

    公开(公告)日：2005-06-29

    申请号：EP03794046.7

    申请日：2003-09-08

    申请人： BEN-GURION UNIVERSITY OF THE NEGEV

    发明人： SEKLER, Israel ,  HERSHFINKEL, Michal ,  SILVERMAN, Ze'ev ,  MORAN, Arie

    IPC分类号： A61K38/17 ,  A61P9/10 ,  A61P9/12

    CPC分类号： A61K38/1709

    摘要： The present invention relates to the use of ZnT-1, originally described as a zinc transporter, in the regulation of L-type calcium channels (LTCC). In this study, the inventors have unexpectedly demonstrated that ZnT-1 physically interacts with LTCC, regulating its function. Most importantly, the inventors have shown that ZnT-1 can regulate intracellular Ca2+ influx, and thus, its intracellular concentration. This is the first demonstration of a natural blocker for LTCC, and it is a promising breakthrough as a potential agent to be used in the treatment and/or prevention of cardiovascular diseases and related indications.

    VARIANT INTEGRIN POLYPEPTIDES AND USES THEREOF
    5.
    发明公开
    VARIANT INTEGRIN POLYPEPTIDES AND USES THEREOF 审中-公开
    变体整合素多肽及其用途

    公开(公告)号：EP1534749A2

    公开(公告)日：2005-06-01

    申请号：EP03810035.0

    申请日：2003-05-12

    申请人： THE GENERAL HOSPITAL CORPORATION

    发明人： ARNAOUT, M. Amin ,  LI, Rui ,  XIONG, Jian-Ping

    IPC分类号： C07K14/705 ,  C12N15/12 ,  G01N33/53

    CPC分类号： C07K14/70553 ,  A61K38/00 ,  C07K14/70546 ,  C07K16/2845

    摘要： Polypeptides comprising all or part of a variant integrin α subunit A domain and its flanking region are described. In solution or in membrane-associated form, the A domain polypeptides of the invention exists predominantly in a high affinity conformation. In the polypeptides of the invention, referred to as variant integrin polypeptides, a crucial isoleucine or glutamic acid residue is altered. For example, the glutamic acid can be either deleted or replaced with different amino acids residue, e.g., glutamine, aspartic acid, or alanine. The variant integrin polypeptides of the invention selectively impair binding or activation-dependent ligands, but not independent ligands. They are useful in screening assays for the identification of molecules that enhance binding of variant polypeptides with impaired binding. In addition, they are useful in distinguishing between activation-dependent ligands and activation-independent ligands. They are also useful for generating antibodies, e.g., monoclonal antibodies, which bind to the impaired form of an integrin. Some such antibodies recognize an epitope that is either not present or not accessible on an integrin that is in the high affinity conformation. The variant integrin polypeptides of the invention can be derived from any integrin α subunit that could be used therapeutically.

    摘要翻译： 描述了包含全部或部分变体整联蛋白α亚基A结构域及其侧翼区的多肽。 在溶液或膜结合形式中，本发明的A结构域多肽主要以高亲和力构象存在。 在本发明的称为变体整联蛋白多肽的多肽中，改变了关键的异亮氨酸或谷氨酸残基。 例如，谷氨酸可以被缺失或被不同的氨基酸残基取代，例如谷氨酰胺，天冬氨酸或丙氨酸。 本发明的变体整联蛋白多肽选择性地损害结合或活化依赖性配体，但不是独立配体。 它们在筛选用于鉴定增强变体多肽与受损结合的结合的分子的分析中是有用的。 另外，它们可用于区分激活依赖性配体和不依赖激活的配体。 它们也可用于产生与整联蛋白受损形式结合的抗体，例如单克隆抗体。 一些此类抗体识别在高亲和力构象的整联蛋白上不存在或不可接近的表位。 本发明的变体整联蛋白多肽可以来源于可以用于治疗的任何整联蛋白α亚基。

    GENFALLEN-KONSTRUKT ZUR IDENTIFIZIERUNG UND ISOLIERUNG VON GENEN
    6.
    发明授权
    GENFALLEN-KONSTRUKT ZUR IDENTIFIZIERUNG UND ISOLIERUNG VON GENEN 失效
    基因捕获构建鉴定及基因的分离

    公开(公告)号：EP0942999B1

    公开(公告)日：2005-05-18

    申请号：EP97952888.2

    申请日：1997-12-05

    申请人： Hölzer, Dieter ,  Von Melchner, Harald

    发明人： VON MELCHNER, Harald, Universitätsklinikum

    IPC分类号： C12N15/65 ,  C12N15/85 ,  C12N5/16 ,  C12Q1/68

    CPC分类号： C12Q1/6897 ,  C12N15/1051

    摘要： The relation relates to a gene trap construct containing a first reporter gene, which, after activation, can activate a second reporter gene, and the use of this gene trap construct for identification and/or isolation of genes, in particular transiently expressed genes. The invention relates further to a cell, preferably a mammal cell, containing the above-mentioned gene trap construct. The invention relates furthermore to the use of this mammal cell for identification and/or isolation of genes, in particular transient genes. In addition, the invention relates to a vector containing the above mentioned gene trap construction, as well as a kit for identifying and/or isolating genes, in particular transient genes, which contains at least the above-mentioned gene trap construct or the above-mentioned vector. Finally, the invention relates to a method for the identification and/or isolation of genes, in particular transient genes.

    Method of culturing cells
    8.
    发明公开
    Method of culturing cells 审中-公开
    培养细胞的方法

    公开(公告)号：EP1516923A2

    公开(公告)日：2005-03-23

    申请号：EP04028722.9

    申请日：2001-05-16

    申请人： THE GENERAL HOSPITAL CORPORATION

    发明人： Toner, Mehmet ,  Eroglu, Ali ,  Toth, Thomas

    IPC分类号： C12N5/02 ,  C12N5/06 ,  A61K31/70

    CPC分类号： A01N1/0221 ,  A01N1/0226

    摘要： A preservation method for biological material having cell membranes includes microinjecting the cells with sugar; preparing the cells for storage; storing the biological material; and recovering the stored biological material from storage. Carbohydrate sugars such as trehalose, sucrose, fructose, dextran, and raffinose, may be used as bio-protective agents.

    摘要翻译： 具有细胞膜的生物材料的保存方法包括用糖显微注射细胞; 准备储存的细胞; 储存生物材料; 并从存储器中回收储存的生物材料。 碳水化合物糖如海藻糖，蔗糖，果糖，葡聚糖和棉子糖可用作生物保护剂。

    NOVEL MOLECULES OF THE PYRIN/NBS/LRR PROTEIN FAMILY AND USES THEREOF
    9.
    发明公开
    NOVEL MOLECULES OF THE PYRIN/NBS/LRR PROTEIN FAMILY AND USES THEREOF 审中-公开
    蛋白质/ NBS / LRR蛋白质家族的新分子及其用途

    公开(公告)号：EP1515981A2

    公开(公告)日：2005-03-23

    申请号：EP02713524.3

    申请日：2002-01-31

    申请人： MILLENNIUM PHARMACEUTICALS, INC. ,  Wyeth

    发明人： BERTIN, John ,  WANG, Weiye ,  BLATCHER, Maria

    IPC分类号： C07H17/00 ,  C07K16/18 ,  C12N15/12 ,  G01N33/53 ,  C12Q1/68

    CPC分类号： C07K14/47 ,  A61K38/00

    摘要： Novel PYRIN-2, PYRIN-3, PYRIN-5, PYRIN-6, PYRIN-7, PYRIN-8, PYRIN-10, and PYRIN-11 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated PYRIN-2, PYRIN-3, PYRIN-5, PYRIN-6, PYRIN-7, PYRIN-8, PYRIN-10, and PYRIN-11 proteins, the invention further provides PYRIN-2, PYRIN-3, PYRIN-5, PYRIN-6, PYRIN-7, PYRIN-8, PYRIN-10, and PYRIN-11 fusion proteins, antigenic peptides and anti-PYRIN-2, -PYRIN-3, -PYRIN-5, -PYRIN-6, -PYRIN-7, -PYRIN-8, -PYRIN-10, and -PYRIN-11 antibodies. The invention also provides PYRIN-2, PYRIN-3, PYRIN-5, PYRIN-6, PYRIN-7, PYRIN-8, PYRIN-10, and PYRIN-11 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a PYRIN-2, PYRIN-3, PYRIN-5, PYRIN-6, PYRIN-7, PYRIN-8, PYRIN-10, or PYRIN-11 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

    摘要翻译： 新颖吡啶-2-吡啶-3-基 - 吡啶-5-基 - 吡啶-6-吡啶-7-吡啶-8，PYR-10，和PYR-11多肽，蛋白质和核酸分子中公开。 除了分离的吡啶-2-吡啶-3-基 - 吡啶-5-基 - 吡啶-6-吡啶-7-吡啶-8，PYR-10，和PYR-11蛋白，本发明还提供吡啶-2-吡啶-3-; 吡啶-5-吡啶-6-吡啶-7-吡啶-8-，PYR-10，和PYR-11融合蛋白，抗原肽和抗 - 吡啶-2-，3 - PYRIN，-PYRIN-5,6 - PYRIN ，-PYRIN-7，-PYRIN-8，-PYRIN-10和-PYRIN-11抗体。 本发明还提供吡啶-2-吡啶-3-基 - 吡啶-5-基 - 吡啶-6-吡啶-7-吡啶-8，PYR-10，和PYR-11的核酸分子，含有的核酸分子的重组表达载体 发明中，到其中的表达载体已被引入和非人类转基因动物的宿主细胞，其中A吡啶-2-吡啶-3-基 - 吡啶-5-基 - 吡啶-6-吡啶-7-吡啶-8，PYR-10，或 PYRIN-11基因已被引入或破坏。 还提供了利用本发明组合物的诊断，筛选和治疗方法。